Centaurus Financial Inc. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 484 shares of the medical instruments supplier’s stock after selling 59 shares during the quarter. Centaurus Financial Inc.’s holdings in Becton, Dickinson and were worth $118,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Northcape Capital Pty Ltd raised its position in shares of Becton, Dickinson and by 3.7% in the 2nd quarter. Northcape Capital Pty Ltd now owns 17,971 shares of the medical instruments supplier’s stock worth $4,370,000 after acquiring an additional 639 shares in the last quarter. LGL Partners LLC purchased a new position in Becton, Dickinson and in the second quarter valued at about $211,000. FFT Wealth Management LLC purchased a new stake in shares of Becton, Dickinson and during the second quarter valued at about $128,000. Folger Nolan Fleming Douglas Capital Management Inc. boosted its holdings in shares of Becton, Dickinson and by 2.9% in the 2nd quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 44,551 shares of the medical instruments supplier’s stock valued at $10,834,000 after buying an additional 1,265 shares in the last quarter. Finally, Papp L Roy & Associates grew its position in shares of Becton, Dickinson and by 5.7% in the 2nd quarter. Papp L Roy & Associates now owns 41,097 shares of the medical instruments supplier’s stock worth $9,994,000 after buying an additional 2,228 shares during the last quarter. 84.25% of the stock is owned by institutional investors.
In other news, Director Claire Fraser sold 387 shares of the stock in a transaction dated Wednesday, August 18th. The shares were sold at an average price of $251.58, for a total transaction of $97,361.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP James C. Lim sold 6,956 shares of Becton, Dickinson and stock in a transaction dated Friday, September 3rd. The shares were sold at an average price of $257.44, for a total value of $1,790,752.64. The disclosure for this sale can be found here. In the last three months, insiders sold 9,093 shares of company stock valued at $2,330,578. Insiders own 0.76% of the company’s stock.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Wednesday, August 4th. The medical instruments supplier reported $2.74 EPS for the quarter, beating the consensus estimate of $2.44 by $0.30. Becton, Dickinson and had a net margin of 9.72% and a return on equity of 16.26%. The business had revenue of $4.89 billion for the quarter, compared to the consensus estimate of $4.51 billion. During the same period in the prior year, the firm earned $2.20 EPS. The business’s revenue for the quarter was up 26.8% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post 12.9 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 30th. Shareholders of record on Thursday, September 9th will be given a dividend of $0.83 per share. This represents a $3.32 annualized dividend and a yield of 1.27%. The ex-dividend date is Wednesday, September 8th. Becton, Dickinson and’s dividend payout ratio is currently 32.55%.
Several equities analysts have issued reports on BDX shares. JPMorgan Chase & Co. lowered shares of Becton, Dickinson and from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $276.93 to $265.00 in a report on Friday, August 6th. Barclays started coverage on Becton, Dickinson and in a research report on Monday, May 24th. They set an “equal weight” rating and a $270.00 target price on the stock. Zacks Investment Research raised Becton, Dickinson and from a “sell” rating to a “hold” rating and set a $262.00 price target for the company in a report on Tuesday, August 17th. Finally, SVB Leerink cut their price objective on shares of Becton, Dickinson and from $260.00 to $250.00 and set a “market perform” rating on the stock in a report on Friday, August 6th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and presently has a consensus rating of “Hold” and a consensus target price of $272.33.
About Becton, Dickinson and
Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.
Read More: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.